What is Boolient?
Boolient, Inc. operates at the intersection of artificial intelligence and healthcare finance, providing a specialized platform designed to streamline revenue cycle management (RCM). The company's core technology focuses on the identification of claim denials and underpayments, utilizing predictive analytics to recover lost revenue for medical providers. In an industry characterized by high administrative burdens and complex reimbursement structures, Boolient offers a data-centric approach that transforms how healthcare organizations manage their financial operations. By automating the detection of billing errors, the firm enables providers to focus on clinical outcomes while ensuring fiscal stability through improved operational transparency.
How much funding has Boolient raised?
Boolient has raised a total of $2.1M across 1 funding round:
Stock/Share Issuance
$2.1M
Stock/Share Issuance (2026): $2.1M, investors not publicly disclosed
Key Investors in Boolient
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Boolient?
With this major enterprise-level funding, Boolient is well-positioned to accelerate its product development roadmap and expand its market footprint. The strategic infusion of capital will likely be directed toward enhancing the firm's machine learning models to further reduce claim rejection rates and improve the accuracy of financial forecasting for large-scale health systems. As the healthcare sector continues to prioritize digital transformation, Boolient's ability to integrate seamlessly into existing electronic health record systems will be a key driver of its future growth. The company is expected to scale its sales and engineering teams to meet the increasing demand for automated RCM solutions, ultimately aiming to set a new standard for efficiency in medical financial management.
See full Boolient company page
